Browse the evidence

Dual or Triple Receptor Agonists (combining GLP-1, GIP, and/or Glucagon) offer superior reduction in liver fat and weight loss compared to selective GLP-1 receptor agonists alone.

Newer 'dual' and 'triple' hormone medications (like Tirzepatide or Efinopegdutide) appear to reduce liver fat and weight more effectively than older GLP-1 drugs alone. These are currently under investigation and may become the preferred treatment for MASLD, especially for those who need significant weight loss and liver fat reduction.

Gastrointestinal adverse events (nausea, vomiting, diarrhea, dyspepsia) associated with tirzepatide contribute minimally (up to 3.1%) to total weight reduction, with weight loss occurring similarly in patients with and without these symptoms.

Do not expect nausea or vomiting to drive your weight loss. Clinical data shows that patients who experience no gastrointestinal side effects lose just as much weight as those who do. Focus on the hormonal mechanism of the drug rather than tolerating discomfort as a sign of efficacy.

Fish oil supplementation (3.85 g/day EPA+DHA) combined with resistance training significantly increases absolute and relative upper-body strength and relative lower-body strength in young adults compared to placebo, without significantly altering lean body mass.

If you are a young, healthy adult doing resistance training 3 times a week, adding 3.85 grams of combined EPA and DHA daily (from fish oil) can help you get stronger, especially in your upper body and relative strength, without necessarily making you bigger. This effect is likely due to improved muscle quality and neural factors, not just muscle growth. Ensure you are getting enough protein (at least 1.2g/kg/day) as this may be required for the fish oil to work effectively.

Obesity increases the risk of nephrolithiasis (kidney stones) through mechanisms including lower urine pH, increased urinary oxalate, uric acid, and sodium excretion, as well as insulin resistance.

Obesity increases your risk of kidney stones by changing your urine chemistry (making it more acidic and increasing stone-forming minerals). Maintaining a healthy weight helps normalize these urinary factors and reduces stone risk.

Weight reduction interventions, including lifestyle changes and ACE inhibition, reduce glomerular hyperfiltration and proteinuria in obese patients with CKD.

If you are overweight and have diabetes, losing weight through diet and exercise can cut your risk of developing kidney disease by 30%. This benefit comes from reducing the strain on your kidneys, not just from better blood sugar control.

Obesity increases the risk of kidney stones (nephrolithiasis) through lower urine pH, increased urinary oxalate, uric acid, and sodium excretion.

Obesity changes your urine chemistry, making you more likely to form kidney stones. This happens because your body excretes more acid and minerals like oxalate. Maintaining a healthy weight helps normalize these urinary factors and reduces stone risk.

Higher BMI is associated with increased feelings of being judged by primary care providers, which correlates with higher rates of avoiding healthcare visits due to weight-related concerns.

If you have a higher BMI, you may feel judged by doctors, and this feeling often stops you from going to appointments. This is a common reaction to stigma, not a reflection of your worth. To overcome this, look for providers who explicitly prioritize respectful communication and ask about your weight management goals proactively.

Food cravings and medical conditions limiting physical activity are the most frequent barriers to weight loss, with food cravings reported by 30.7%-49.9% of respondents.

Food cravings and physical limitations are the top barriers to weight loss for most people. These are common and can often be addressed through education and access to resources like dietitians and exercise facilities.

Implementing an intensive 18-month behavioral weight loss intervention in community mental health settings for adults with serious mental illness costs approximately $501 per kilogram of weight lost, or $95 per participant per month.

If you run a community mental health program, you can implement an 18-month weight loss program for about $95 per patient per month. The key is to use existing staff and kitchen budgets where possible, and to train your own staff to deliver the intervention to save on hiring external coaches. The cost per kilogram lost is competitive with commercial programs, making it a viable option for improving patient health.

An academia-industry partnership model for community-based controlled feeding studies enables high-fidelity macronutrient differentiation and long-term adherence, overcoming the feasibility and cost barriers of traditional hospital-based metabolic ward trials.

This paper does not offer a direct diet plan for individuals, but it validates that high-adherence dietary interventions are possible in real-world settings if logistical barriers are removed. For researchers or program designers, partnering with commercial food services (like Sodexo) allows for the creation of palatable, differentiated diets that participants can actually follow long-term. For individuals, the key takeaway is that removing the burden of meal planning and procurement (via meal delivery or similar services) significantly improves adherence to specific macronutrient targets.

GLP-1 receptor agonists (semaglutide) significantly improve quality of life and exercise capacity in obese patients with heart failure with preserved ejection fraction (HFpEF), primarily through substantial weight loss.

For obese patients with HFpEF, GLP-1 agonists like semaglutide are effective at improving quality of life and exercise capacity, largely by driving significant weight loss (approx. 13%). While these drugs are promising, their benefits appear closely tied to weight reduction rather than unique cardiac mechanisms. Therefore, they should be viewed as one option among others, including caloric restriction and supervised exercise, which may offer similar benefits at a lower long-term cost.

Once-weekly semaglutide (0.5 mg and 1.0 mg) as an add-on to metformin significantly improves glycemic control (HbA1c), reduces body weight, and lowers blood pressure compared to once-daily sitagliptin in patients with type 2 diabetes.

For patients with Type 2 Diabetes on metformin who need better blood sugar and weight control, switching to once-weekly semaglutide is more effective than switching to the oral drug sitagliptin. Semaglutide lowers HbA1c, weight, and blood pressure more significantly. However, be aware that semaglutide carries a higher risk of side effects and treatment discontinuation compared to sitagliptin.

A 20g collagen hydrolysate/milk protein blend stimulates muscle protein synthesis (MPS) in older men to an equivalent degree as a calorie-matched milk protein blend containing higher essential amino acids, despite lower leucine content.

For older adults looking to maintain muscle, a 20g protein supplement containing a mix of collagen and milk protein is just as effective at stimulating muscle building as a standard milk protein supplement, even if the milk-only version has more leucine. The key advantage is that the collagen blend can be delivered in a smaller volume (125ml vs 200ml), which may be easier to consume for those with reduced appetite.

Bariatric surgery (RYGB, SG, or LAGB) produces significantly greater sustained weight loss and higher rates of type 2 diabetes remission compared to intensive lifestyle interventions (ILI) or diabetes support and education (DSE) in patients with type 2 diabetes and obesity.

For individuals with Type 2 Diabetes and obesity, bariatric surgery is significantly more effective than lifestyle changes alone for losing weight and reversing diabetes. While lifestyle changes (like the Intensive Lifestyle Intervention in this study) can lead to modest weight loss (~6%) and minimal diabetes remission (~1%), surgery leads to substantial weight loss (~19%) and much higher remission rates (~7-23%). Surgery should be considered a highly effective medical option for those who meet criteria, rather than just a last resort after failed lifestyle attempts.

A six-month home-based physical activity and nutrition intervention produces significant improvements in metabolic syndrome parameters, but these benefits largely plateau and do not significantly improve further during an 18-month follow-up without additional booster interventions.

If you start a health program, expect the biggest changes in the first 6 months. To keep those gains, you cannot just stop. You need a 'maintenance mode' plan with regular check-ins, even if they are brief, to prevent your habits from slowly drifting back to old patterns.

Urban design that promotes physical activity and provides green space reduces cardiovascular mortality and risk factors, whereas urban environments that hinder activity and lack green space increase risk.

Prioritize living in or visiting areas with significant tree canopy and green space. If you live in a dense urban area, seek out parks and green corridors. These spaces not only encourage physical activity but also mitigate heat stress and air pollution, directly lowering cardiovascular risk.

Achieved weight loss, rather than dietary protein quantity or red meat inclusion, is the primary driver of improved glucose control and body composition in adults with type 2 diabetes.

If you have Type 2 Diabetes, focus on losing weight rather than obsessing over whether your protein intake is 'high' or if you eat beef. This study shows that losing weight improves your blood sugar and body composition regardless of whether you eat a high-protein diet with beef or a normal-protein diet without it. Choose a dietary pattern you can stick to that creates a calorie deficit, and the health benefits will follow.

Once-weekly subcutaneous semaglutide 2.4 mg significantly improves weight-related quality of life (WRQOL) and health-related quality of life (HRQOL) in East Asian adults with overweight or obesity, specifically enhancing physical functioning, psychosocial well-being, and total quality of life scores compared to placebo.

If you are an East Asian adult with overweight or obesity, once-weekly semaglutide 2.4 mg, combined with a modest 500-kcal daily calorie deficit and 150 minutes of weekly physical activity, has been shown to significantly improve your physical functioning, psychosocial well-being, and overall quality of life compared to placebo. This treatment helps you feel better in social situations and perform daily activities more comfortably.

Vitamin E supplementation (800 IU daily) improves steatohepatitis, hepatic steatosis, and inflammation in adults with MASH who do not have diabetes, but does not improve fibrosis.

If you have MASH and do not have diabetes, your doctor may recommend 800 IU of Vitamin E daily. This dose has been shown to reduce liver inflammation and fat over 96 weeks, though it does not reverse scarring (fibrosis).

Discontinuation of GLP-1 receptor agonists leads to significant weight regain (approx. two-thirds of lost weight) and loss of cardiometabolic benefits, driven partly by a surge in ghrelin.

If you stop taking GLP-1 medications, you will likely regain most of the weight you lost. This is a physiological response (ghrelin surge), not a failure of willpower. To maintain weight loss, you must either stay on the medication indefinitely or switch to a more durable intervention like surgery.

Tirzepatide treatment produces similar improvements in glycemic control (HbA1c) and body weight in patients with early-onset type 2 diabetes (diagnosed before age 40) compared to those with later-onset type 2 diabetes.

If you were diagnosed with type 2 diabetes before age 40, you may have heard that your condition is harder to treat. This analysis of major clinical trials shows that the medication tirzepatide works just as well for you as it does for older patients, significantly lowering blood sugar and body weight. You should discuss this option with your doctor, as it addresses the specific metabolic challenges often seen in early-onset diabetes.

Performing leg extension exercises with a reduced hip flexion angle (approx. 40°) produces significantly greater hypertrophy in the rectus femoris compared to a standard upright hip angle (90°), while having no differential effect on the vastus lateralis.

If your goal is to maximize growth in the rectus femoris (the muscle in the middle of your thigh), adjust your leg extension machine to lean back slightly (approx. 40 degrees of hip flexion) rather than sitting fully upright. This position likely places the rectus femoris at a more optimal length for growth. Note that this change does not appear to affect the vastus lateralis (outer thigh) growth, so both positions are valid for general quad development.

In patients with type 2 diabetes who have switched from metformin to a second-line antidiabetes medication, a 6-month weight loss is associated with improved glycemic control (lower A1c) and reduced diabetes-specific pharmacy costs.

If you have type 2 diabetes and are considering a medication change after metformin, achieving even modest weight loss over 6 months can significantly improve your blood sugar control and lower your pharmacy bills. Focus on sustainable weight management as part of your treatment plan.

Dietary patterns characterized by high intake of alcohol, fast food, fried/processed foods, and meat are associated with increased subclinical cardiovascular damage (specifically higher left ventricular mass and carotid-femoral pulse-wave velocity), with associations varying significantly by generation and sex.

Focus on reducing alcohol, processed meats, fried foods, and fast foods, as these patterns are linked to higher cardiovascular risk markers. Be aware that these risks may manifest differently depending on your age and sex; older men may see higher arterial stiffness, while women may see higher heart muscle mass. Tailor your diet to your specific demographic subgroup for better cardiovascular protection.